Scientists have imaged the toxic clumps and fibres made by expanded huntingtin with cutting-edge microscopes, helping us to understand the exact way they can be assembled and how their structure could ...

In Huntington’s disease research, biomarkers are the secret weapon for spotting treatment effects. A new blood study uncovers two proteins, CAP1 and CAPZB, that, with additional work, could help track ...

Some childhood experiences stay with us, quietly shaping how we feel as adults. For those raised in families with Huntington’s disease, this new study helps make sense of those feelings, and reminds ...

A well-studied, widely used class of drugs for heart health may have benefits for Huntington’s disease. A new paper associated beta-blocker use with delayed onset and slower disease progression.

The gene MSH3 is getting a lot of attention in HD research lately. New findings suggest MSH3 lowering could halt CAG repeat expansions, offering a new therapeutic avenue.

Data from GENERATION HD1, the Phase 3 clinical trial testing the huntingtin-lowering drug tominersen, have just been published in a scientific journal. The trial ended a while back, so why is this an ...

A new study led by researchers at University College London explored a promising new way to potentially slow down Huntington disease (HD) by reducing the levels of a key DNA repair protein, called ...

Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, but only the higher dose will move forward. What does this ...

Researchers have updated the system that classifies Huntington’s disease progression. Tracking progression in 4 stages will make clinical trial screening and data interpretation easier and faster, and ...

Top line results of the PROOF-HD study, run by Prilenia Therapeutics and testing pridopidine, have been announced at the American Academy of Neurology convention. Sadly the trial outcome was negative.

Casgevy is the first CRISPR-based drug to make its way through the approval process, all but curing Sickle Cell Disease and it’s paving the way for similar drugs targeting other diseases. Is ...

The HDBuzz editorial team had a virtual sit-down with HDBuzz founder, editor emeritus, Huntington’s disease (HD) researcher, and neurologist Professor Ed Wild. We laughed, we cried… actually we just ...